Last C$0.69 CAD
Change Today 0.00 / 0.00%
Volume 0.0
DMA On Other Exchanges
As of 12:47 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

diamedica inc (DMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/5/13 - C$1.49
52 Week Low
06/26/14 - C$0.54
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DIAMEDICA INC (DMA)

Related News

No related news articles were found.

diamedica inc (DMA) Related Businessweek News

No Related Businessweek News Found

diamedica inc (DMA) Details

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company’s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Founded in 2000

diamedica inc (DMA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$276.5K
Chief Financial Officer
Total Annual Compensation: --
Executive Vice President
Total Annual Compensation: C$234.0K
Vice-President of Research
Total Annual Compensation: C$177.0K
Vice President of Finance
Total Annual Compensation: C$74.5K
Compensation as of Fiscal Year 2013.

diamedica inc (DMA) Key Developments

DiaMedica Inc. Promotes Mark Robbins to Executive Vice President

DiaMedica Inc. announced the promotion of Mark Robbins, Ph.D., J.D., to Executive Vice President. Dr. Robbins joined DiaMedica in December 2012 as Vice President, Clinical and Regulatory Affairs. He will continue to oversee the Company's clinical development efforts. Prior to joining DiaMedica, Dr. Robbins spent 15 years with Upsher-Smith Laboratories, advancing to Executive Vice President, Legal, Scientific and Technical Operations, Chief Scientific Officer and Assistant Secretary, where he oversaw the clinical and regulatory strategies for several drugs ranging from R&D to manufacturing and Phase I to Phase III.

Diamedica Inc. Proposes Amendments to the Articles of Incorporation and By-Laws

Diamedica Inc. proposed amendments to the articles of incorporation and by-laws of the corporation at the annual general meeting to be held on July 24, 2014.

DiaMedica Announces Board Changes

DiaMedica Inc. announced the appointment of Richard Pilnik as Chairman of the company's Board of Directors. Mr. Pilnik has been a member of DiaMedica's Board of Directors since 2009. He recently retired as Executive Vice President and President of Quintiles Commercial Solutions. Mr. Pilnik previously spent 25 years at Eli Lilly, where he held several leadership positions including Group Vice President and Chief Marketing Officer. Mr. Pilnik will replace Rick Pauls as Chairman. Mr. Pauls will continue as President & CEO and a member of the Board of Directors. Mr. Pilnik has served on the board of directors of Elan Corporation.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DMA:CN C$0.69 CAD 0.00

DMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DMA.
View Industry Companies

Industry Analysis


Industry Average

Valuation DMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAMEDICA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at